Augmedics, a pioneer in augmented reality surgical image guidance, announced today that it has raised $36 million in an over-subscribed Series C financing with an international syndicate of Israel-US investors. This comes only eight months after the company closed a $21 million Series B financing, bringing the total funding to date to $63 million.
H.I.G. Capital, Revival Healthcare Capital, and Almeda Ventures led this financing round and are joined by two strategic investors including HCA Healthcare Health Insight Capital, as well as existing investor XR Invest (formally known as AO Invest). With this financing Bruce Robertson (H.I.G.) and Rick Anderson (Revival) will join the board of Augmedics and Amir Blatt (Almeda) will join as a board observer.
In December 2019, Augmedics announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the launch of its xvision Spine System (XVS) in the U.S., the first and only FDA-approved augmented reality surgical image guidance system. The xvision Spine System allows surgeons to visualize the 3D spinal anatomy of a patient during surgery as if they had “x-ray vision,” and to accurately navigate instruments and implants while looking directly at the patient, rather than a remote screen. The system is designed to revolutionize how surgery is performed by giving the surgeon better visualization, control, and accuracy.